KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor
Authors:
Abstract
The KAI1/CD82 gene, the product of which is a member of the transmembrane-4 superfamily, is a suppressor of metastasis; as a result, it is inversely associated with tumor progression and is a favorable prognostic factor in some tumors. This study was performed to determine the prognostic value of KAI1/CD82 protein levels in nonsmall cell lung carcinoma (NSCLC). In addition, levels of KAI1/CD82 expression in metastatic lesions were determined and compared with those in primary NSCLC lesions. KAI1/CD82 expression in 200 NSCLC patients who underwent potentially curative surgery was immunohistochemically detected with C33, an anti-KAI1/CD82 monoclonal antibody. According to the degree of KAI1/CD82 positive cancer cells within the tumor tissue, each sample was classified as KAI1/CD82 positive, KAI1/CD82 reduced, or KAI1/CD82 negative. Sixty-five samples (32.5%) were KAI1/CD82 positive, 31 (15.5%) were reduced, and 104 (52%) were negative. There was no significant association between KAI1/CD82 expression and clinicopathologic factors, but patients who were positive for KAI1/CD82 expression had significantly favorable prognoses for overall survival (P = 0.0026) and disease free survival (DFS; P = 0.0007) compared with the other groups. In particular, among patients with adenocarcinoma, similar results were even more significant. In multivariate analysis, immunohistochemical KAI1/CD82 expression in patients with NSCLC was an independent prognostic factor for overall survival and DFS; in those with adenocarcinoma, it was an even more valuable factor. In some patients with NSCLC, especially those with adenocarcinoma, KAI1/CD82 expression levels in metastatic lesions were diminished compared with levels of expression in the primary lung lesions. The immunohistochemically determined level of KAI1/CD82 expression in NSCLC cells within tumor tissue appears to be a favorable prognostic factor for overall survival as well as DFS. The results of this study suggest that decreased KAI1/CD82 expression may be associated with tumor progression and enhanced metastatic potential in some patients with this disease. Cancer 1998;83:466-474. © 1998 American Cancer Society.Keywords
This publication has 17 references indexed in Scilit:
- Localization of the Transmembrane 4 Superfamily (TM4SF) Member PETA-3 (CD151) in Normal Human Tissues: Comparison with CD9, CD63, and α5β1 IntegrinJournal of Histochemistry & Cytochemistry, 1997
- KAI1 , a Metastasis Suppressor Gene for Prostate Cancer on Human Chromosome 11p11.2Science, 1995
- The ins and outs of the transmembrane 4 superfamilyImmunology Today, 1994
- Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA.Journal of Experimental Medicine, 1993
- Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanomaInternational Journal of Cancer, 1993
- Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility.Journal of Experimental Medicine, 1991
- Novel structurally distinct family of leucocyte surface glycoproteins including CD9, CD37, CD53 and CD63FEBS Letters, 1991
- A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23European Journal of Immunology, 1991
- TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins.Molecular and Cellular Biology, 1990
- The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OX-44 antigen.Journal of Experimental Medicine, 1989